Previously, subgroup analyses from EMPA-REG OUTCOME or CANVAS Program did not show a significant reduction in MI or stroke by SGLT2 inhibitors9,10; however, these secondary endpoints could not be proven with relatively small numbers of trial participants. This evidence concerns the gene SLC5A2 and Stroke.